Zobrazeno 1 - 10 of 15 pro vyhledávání: '"Mary Flanagan Quinn"'
1
REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer
Autor: Bennett Thilagar, Bradley Brown, Arnold L. Oronsky, Tony R. Reid, Nacer Abrouk, Corey A. Carter, Erica Burbano, Angelique Coyle, Bryan Oronsky, Scott Caroen, Gina Varner, Curtis Scribner, Lindsey Ferry, Christopher A. Larson, Mary Flanagan Quinn
Publikováno v: Future Oncology. 15:3427-3433
RRx-001 is a cysteine-directed anticancer alkylating agent with activity in a Phase II study in platinum refractory small cell lung cancer. Here, we describe the design of REPLATINUM, an open-label, Phase III trial. 120 patients with previously plati
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb0750e6416fb0e065a006b84316412c
https://doi.org/10.2217/fon-2019-0317
Zobrazit plný text záznamu
2
An explorary analysis of a COVID-truncated REPLATINUM phase 3 trial in SCLC
Autor: Ralph J. Hauke, Scott Caroen, Jeannie Williams, Xiaohui Wang, Mary J. Fidler, Alberto Chiappori, Erica Burbano, Xiaoning Guo, Nacer Abrouk, Muhammad A. Salamat, Mary Flanagan Quinn, Tony R. Reid
Publikováno v: Journal of Clinical Oncology. 39:e20594-e20594
e20594 Background: RRx-001 is a small molecule immunotherapeutic in Phase 3 for the treatment of SCLC that is associated with M2-M1 tumor associated macrophage (TAM) repolarization with CD47 downregulation, vascular normalization and reversal of chem
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a132522ba36543ffad865c6dacc35839
https://doi.org/10.1200/jco.2021.39.15_suppl.e20594
Zobrazit plný text záznamu
3
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
Autor: Christina Brzezniak, Mary Flanagan Quinn, Bruno Schmitz, Jan Scicinski, Bryan Oronsky, Aiste Degesys, Pedro Cabrales, John Jenkins, Tony R. Reid, Scott Caroen, Corey A. Carter, P. Gabriel Peterson
Publikováno v: Case Reports in Oncology
Case reports in oncology, vol 9, iss 1
Case Reports in Oncology, Vol 9, Iss 1, Pp 164-170 (2016)
Neuroendocrine tumors (NETs) are grouped together as a single class on the basis of histologic appearance, immunoreactivity for the neuroendocrine markers chromogranin A and synaptophysin, and potential secretion of hormones, neurotransmitters, neuro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d4601de79543db51deb5057abe003d5
https://doi.org/10.1159/000444633
Zobrazit plný text záznamu
4
Phase I pilot study of RRx-001 + nivolumab in patients with traditionally non-checkpoint inhibitor-responsive cancers (PRIMETIME)
Autor: Bryan T. Oronsky, Jeannie Williams, Christina Brzezniak, Mary Flanagan Quinn, Corey Carter, Scott Caroen
Publikováno v: Journal of Clinical Oncology. 38:e15119-e15119
e15119 Background: RRx-001 is a minimally toxic small molecule that downregulates CD47 via Myc inhibition and repolarizes tumor-associated macrophages (TAMs). A phase 1 pilot study was undertaken to determine the safety and feasibility of RRx-001 and
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c34f002f09d80c6971fd38a695728ab9
https://doi.org/10.1200/jco.2020.38.15_suppl.e15119
Zobrazit plný text záznamu
5
Phase I study (PAYLOAD) of RRx-001 + irinotecan in patients with advanced solid malignancies
Autor: Nacer Abrouk, Corey A. Carter, Edward J. Kim, Bryan T. Oronsky, Elizabeth Poplin, Tony R. Reid, Scott Caroen, Mary Flanagan Quinn
Publikováno v: Journal of Clinical Oncology. 38:e16031-e16031
e16031 Background: RRx-001 is a downregulator of CD-47 and SIRP-alpha, which demonstrated a clinically meaningful improvement in OS and PFS vs. regorafenib when dosed sequentially with irinotecan in a 3rd/4th line colorectal cancer randomized trial c
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c392fcae0dc0c9142d161d2f3485f961
https://doi.org/10.1200/jco.2020.38.15_suppl.e16031
Zobrazit plný text záznamu
6
Correlation of decreased expression of PD-L1 on circulating tumor cells and clinical benefit in SCLC Patients treated with RRx-001, a CD47 downregulator, in a phase II trial
Autor: Corey Carter, Pedro Cabrales, Sunmin Lee, Bryan T. Oronsky, Tony R. Reid, Akira Yuno, Mary Flanagan Quinn, Min-Jung Lee, Jane B. Trepel, Jonathan R. Baker, Nacer Abrouk, Scott Caroen, Yusuke Tomita
Publikováno v: Journal of Clinical Oncology. 38:9062-9062
9062 Background: In a Phase 2 trial called QUADRUPLE THREAT (QT) (NCT02489903), where 2nd line+ small cell lung cancer (SCLC) patients were treated with RRx-001 and a platinum doublet, the programmed death-ligand 1 (PD-L1) status of circulating tumor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e46144e8ee8094949d89752458ad9b1a
https://doi.org/10.1200/jco.2020.38.15_suppl.9062
Zobrazit plný text záznamu
7
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient after Priming with RRx-001
Autor: H. Lybeck, Jane B. Trepel, Christina Brzezniak, Corey A. Carter, Karen Zeman, Mary Flanagan Quinn, Scott Caroen, Regina M. Day, Arnold L. Oronsky, Nacer Abrouk, Jan Scicinski, Tony R. Reid, Bryan Oronsky, Pedro Cabrales, Christopher A. Larson
Publikováno v: Clinical Medicine Insights: Oncology, Vol 10 (2016)
Clinical Medicine Insights. Oncology
Clinical Medicine Insights: Oncology, Vol 2016, Iss 10, Pp 105-108 (2016)
As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse t
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6122f64ee2dc398450df87eea0d80ecc
http://hdl.handle.net/10138/232079
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje